Centogene MOx 2.0

Centogene has launched an expanded version of MOx, the company's multiomic diagnostic portfolio, which now includes transcriptome analysis. The new version, MOx 2.0, combines whole-genome or whole-exome sequencing, biochemical testing, and RNA sequencing. According to the company, the integration of RNA sequencing provides a more complete picture of a patient's disease biology and drug response.